So here's a classic private equity move: Hologic Inc. (HOLX), the women's health company, is officially going private. The company said Tuesday it has completed its acquisition by funds managed by Blackstone Inc. (BX) and TPG Inc. (TPG).

That means Hologic's common stock has stopped trading and will be delisted from the Nasdaq Stock Market. If you owned shares, you're now a former shareholder.

The company agreed to this back in October in a deal that values it at about $18.3 billion. The purchase price works out to $79 per share, which represented a pretty sweet 46% premium to Hologic's closing share price on May 23, 2025. Not a bad bump if you were holding then.

Now that the transaction is done, shareholders get $76 per share in cash, plus this interesting little extra: a non-tradable contingent value right (CVR) worth up to $3 per share. Think of it as a performance bonus. The CVR will be paid in two potential installments of up to $1.50 each.

Here's how that bonus works: it's tied to Hologic's Breast Health business hitting specific global revenue milestones in fiscal 2026 and 2027. So the private equity owners are basically saying, "Hit these targets, and we'll throw a little extra cash your way." The CVR gets distributed at closing, so shareholders have it now—they just have to wait to see if it pays out.

This is a pretty significant shift for a company focused on women's health. The backing from Blackstone and TPG is expected to support Hologic's innovation and growth plans going forward. Private equity ownership often means more flexibility to make long-term investments without worrying about quarterly earnings reports.

And with the deal done, there's a leadership change too. Hologic appointed José (Joe) E. Almeida as chief executive officer, effective immediately. He's taking over from Stephen MacMillan, who recently retired after more than 12 years as chairman, president and CEO. New owners, new CEO—the full private equity package.